MorphoSys (ETR:MOR) Reaches New 12-Month High at $68.00

MorphoSys AG (ETR:MOR) shares reached a new 52-week high during mid-day trading on Wednesday . The company traded as high as €68.00 ($72.34) and last traded at €67.70 ($72.02), with a volume of 122121 shares trading hands. The stock had previously closed at €67.70 ($72.02).

MorphoSys Stock Performance

The company has a debt-to-equity ratio of 526.17, a current ratio of 3.08 and a quick ratio of 3.49. The company has a market cap of $2.55 billion, a price-to-earnings ratio of -12.24, a price-to-earnings-growth ratio of 0.06 and a beta of 0.61. The business has a 50 day simple moving average of €66.05 and a 200 day simple moving average of €42.68.

MorphoSys Company Profile

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity.